DOCSLIB.ORG

Psychoactive Medications Grouped by Drug Class and Foods Studied Tor Psychoactive Effects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Psychoactive Medications Grouped by Drug Class and Foods Studied Tor Psychoactive Effects Psychoactive Medications Grouped by Drug Class and Foods Studied tor Psychoactive Effects Drug and class Trade name(s) CNS stimulants amphetamine Benzedrine® deanol Deaner® dextroamphetamine (D-amphetamine) Dexedrine® dextroamphetamine/amphetamine" Adderall® levoamphetamine (L-amphetamine) Cydril® methamphetamine Desoxyn® methylphenidate Ritalin® pemoline Cylert® Neuroleptics (antipsychotics, "major tranquilizers") Phenothiazines chlorpromazine Largactil®, Thorazine® ftuphenazine (decanoate) Prolixin®, Modecate® mesoridazine Serentil® peracetazine Quide® pericyazine Neulactil® perphenazine Trilafon® pipothiazine palrnitate Piportil® prochlorperazine Compazine®, Stemetil® promazine Sparine® thioridazine Mellaril® triftuoperazine Stelazine® Thioxanthenes chlorprothixene Taractan®, Tarasan® ftupenthixol (decanoate) Depixol® thiothixene Navane® Benzisothiazolyl piperazines ziprasidone Zeldox® Practitioner's Guide to Psychoactive Drugs for Children and Adolescents (Second Edition), Werry and Aman, eds. Plenum Publishing Corporation, New York, 1999. 471 472 Psychoactive Medications Grouped by Drug Class Drug and class Trade name(s) Neuroleptics (antipsychotics, "major tranquilizers") (cont.) Benzisoxazoles risperidone Risperdal® Butyrophenones droperidol Droleptan® haloperidol Haldol®, Serenace® pipamperon Dipiperon® Dibenzothiazepines quetiapine Seroquel® Dibenzoxazepines loxapine Loxitane® Dihydroindolones molindone Moban® Diphenylbutylpiperidines pimozide Orap® Dibenzodiazepines clozapine Clozaril®, Leponex® Thienobenzodiazepines olanzapine Zypexa® sertindole Serlect® Antiparkinson drugsb amantadine Symrnetrel® benztropine Cogentin® biperiden Akineton® diphenhydramine Benadryl® ethopropazine Parsidol® procyclidine Kemadrin® trihexyphenidyl Artane® Antidepressant drugs Tricyclies amitriptyline Elavil®, Amitril®, Endep® clomipramine Anafranil desipramine Norpramin®, Pertofrane® doxepin Sinequan®, Adapin® imipramine Tofranil®, Janimine®, Dumex® nortriptyline Pamelor®, Aventyl®, Allegron® protriptyline Vivactil®, Concordin® trimipramine Surmontil® Atypical antidepressants amoxapine Asendin® bupropion Wellbutrin® maprotiline Ludiomil® Selective serotonin reuptake inhibitors (SSRIs) fluoxetine Prozac® fluvoxarnine Luvox® paroxetine Paxil® sertraline Zoloft® Serotonin agonists and antagonists nefazadone Serzone® trazodone Desyrel® Serotonin-norepinephrine dual reuptake inhibitor venlafaxine Effexor® Monoamine oxidase inhibitors (MAOIs) isocarboxazid Marplan® moclobemide Aurorix® Psychoactive Medications Grouped by Drug Class 473 Drug and c1ass Trade name(s) Antidepressant drugs (cont.) Monoamine oxidase inhibitors (MAOIs) (cont.) phenelzine Nardil® selegiline Deprenyl® tranylcypromine Parnate® Novel antidepressants mirtazapine Remeron® Other hypericum extract (active ingredient in St. John's wort) Kira® Mood stabilizers (antimanics) carbamazepinec Tegretol® c10nazepamc Klonopin®, Rivotril® lithium carbonate Eskalith®, Lithane®, Lithobid®, Lithonate®, Lithotab® lithium citrate Cibalith-S® valproic acidc Depakote®, Depakene®, Epilim® Antiepileptics (anticonvulsants) Barbiturates mephobarbital Mebaral® phenobarbital Gardenal®, Luminal® primidone Mysoline® Hydantoins ethotoin Peganone® mephenytoin Mesantoin® phenytoin Dilantin® Succinimides ethosuximide Zarontin® methsuximide Celontin® phensuximide Milontin® Benzodiazepines c10nazepamc Klonopin®, Rivotril® clorazepateC Tranxene® diazepamc Valium® lorazepamc Ativan® GABA agonists tiagabine Gabitril®, Tiabex® valproic acidldivalproex Depakene®, Depakote®, Epilim® vigabatrin (-y-vinyl GABA) Sabril® Membrane-acting or multiple mechanisms carbamazepine Tegretol® felbamate Felbatol® gabapentin Neurotin® lamotrigine Lamictal® topiramate Topamax® New/under development c10bazam flunarizine Sibelium® GW 534 10rec1ezole oxcarbazepine progabide Gabren® remacemide rufinamide stiripentol zonisamide 474 Psychoactive Medications Grouped by Drug Class Drug and class Trade name(s) Sedative-hypnotics Antihistamines diphenhydramine Benadryl® hydroxyzine Atarax®, Vistaril® promethazine Phenergan® trimeprazine Temaril®, Vallergan® Benzodiazepines ("minor tranquilizers") alprazolam Xanax® chlordiazepoxide Librium® clonazepamc Klonopin®, Rivotril® clorazepateC Tranxene® diazepamc Valium® flurazepam Dalmane® lorazepamc Ativan® nitrazepam Mogadon® oxazepam Serax®, Serapax® prazepam Verstran® temazepam Restoril®, Euhypnos® triazolam Halcion® Benzodiazepine analogues zopiclone Imovane® Atypical anxiolytics buspirone BuSpar® Other alcohol chloral hydrate Noctec® melatonin Melatonex®, Somniset® meprobamate Equanil®, Miltown® secobarbital Seconal® Cl2-adrenergic agonists clonidine Catapres®, Combipres® guanfacine Tenex® Opiate blockers naloxone Narcan® naltrexone Trexan® ß blockers acebutolol Sectral® atenolol Tenoretic®, Tenormin® bisoprolol Zebeta® esmolol Brevibloc® labetolol Normodyne® metoprolol LopressorllP, Toprol® nadolol Corgard® oxprenolol Oxanol®, TrasicorIIP penbutolol Levatol® propranolol Inderal®, Inderide® sotalol Betapace®, SotacorllP, Sotalex® timolol Blocadren®, Timoptic® Nootropics aniracetam Draganon®, Reset®, Sarpul® etiracetam nefiracetam oxiracetam Neuromet®, Neuractiv® piracetam Avigilen®, Nootropil®, Nootropyl®, othersd pramiracetam Neupramif®, Remen® rolziracetam Psychoactive Medications Grouped by Drug elass 475 Drug and class Trade name( s) Miseellaneous Fenflurarnine (serotoninolytie agent) (withdrawn from the Pondimin®, Ponderax® market) 5-Hydroxytryptophan (serotonin preeursor) L-tryptophan (serotonin preeursor) (off the market in the United States) Foods and and substanees present in food Foods/derivatives aspartame Equal®, NutraSweet® eaffeine ehocolate eholine sugar tryptophan tyrosine Food additives benzoie aeid monosodium glutamate tartrazine Vitamins/minerals iron vitamin B6 zine aDextroamphetamine saccharate, dextroamphetamine sulfate, amphetamine aspartate, amphetamine sulfate. bDrug belongs to more !han one clinical group. cPrequently used 10 !real extrapyramidal side effects of neuroleplic drugs; seldom used as psychotropic drugs. dCerebroforte®, Cerebrospan®, Cetam®, Dinagen®, Encefalux®, Encetrop®, Euvifor®, Gabacet®, Genogris®, Memo-Puren®, Nootron®, Nootrop®, Normabrain®, Norzetam®, Pirroxil®, Psycoton®, Stimucortex®. Major Psychoactive Medications Ordered by Trade ame Trade name Generic name Class Adapin® doxepin Antidepressant Adderall® dextroamphetamine/amphetamine CNS stimulant Akineton® biperiden Antiparkinson Allegron® nortriptyline Antidepressant Amitril® amitriptyline Antidepressant Anafranil® c10mipramine Antidepressant Artane® trihexyphenidyl Antiparkinson Asendin® amoxapine Antidepressant AtaraxiII> hydroxyzine Sedative-hypnotic Ativan® lorazepam Sedative-hypnotic, antiepileptic Aurorix® mocIobemide Antidepressant Aventyl® nortriptyline Antidepressant Avigilen® piracetam Nootropic Benadryl® diphenhydramine Sedative-hypnotic, antiparkinson Benzedrine® amphetamine CNS stimulant Betapace® sotalol ß-Blocker Blocadren® timolol ß-Blocker Brevibloc® esmolol ß-Blocker BuSpar® buspirone Sedative-hypnotic (anxiolytic) Catapres® c10nidine Antihypertensive, Ot2-adrenergic agonist Celontin® methsuximide Antiepileptic Cerebroforte® piracetam Nootropic Cerebrospan® piracetam Nootropic Cetam® piracetam Nootropic Cibalith-S® lithium citrate Mood stabilizer/antimanic Clozaril® c10zapine Neuroleptic Cogentin® benztropine Antiparkinson Combipres® c10nidine Antihypertensive, Ot2-adrenergic agonist Compazine® prochlorperazine Neuroleptic Concordin® protriptyline Antidepressant Corgard® nadolol ß-Blocker Cydril® levoamphetamine CNS stimulant Cylert® pemoline CNS stimulant Dalmane® flurazepam Sedative-hypnotic Deaner® deanol CNS stimulant Practitioner s Guide to Psychoactive Drugs for Children and Adolescents (Second Edition), Werry and Aman, eds. Plenum Publishing Corporation, New York, 1999. 477 478 Major Psychoactive Medications Ordered by Trade Name Trade name Generic name Class Depakene® valproic acid Antiepileptic, mood stabilizer/antimanic Depakote® valproic acid Antiepileptic, mood stabilizer/antimanic Depixol® flupenthixol (decanoate) Neuroleptic Deprenyl® selegiline Antidepressant Desoxyn® methamphetamine CNS stimulant Desyrel® trazodone Antidepressant Dexedrine® dextroamphetarnine (D-amphetamine) CNS stimulant Dilantin® phenytoin Antiepileptic Dinagen® piracetam Nootropic Dipiperon® pipamperon N euroleptic Draganon® aniracetam Nootropic Droleptan® droperidol Neuroleptic Dumex® imipramine Antidepressant Elavil® amitriptyline Antidepressant Encefalux® piracetam Nootropic Encetrop® piracetam Nootropic Endep® amitriptyline Antidepressant Epilim® valproic acid Antiepileptic, mood stabilizer/antimanic Equanil® meprobamate Sedati ve-hypnotic Eskalith® lithium carbonate Mood stabilizer/antimanic Euhypnos® temazepam Sedative-hypnotic Euvifor® piracetam Nootropic Felbatol® felbamate Antiepileptic Gabacet® piracetam Nootropic Gabitril® tiagabine Antiepileptic Gabren® progabide Antiepileptic Gardenal® phenobarbital Antiepileptic Genogris® piracetam Nootropic Halcion® triazolam sedative-hypnotic Haldol® haloperidol Neuroleptic Imovane® zopiclone Sedative-hypnotic Inderal® propranolol ß-Blocker Inderide® propranolol ß-Blocker Janimine® imipramine Antidepressant Kemadrin® procyclidine Antiparkinson Klonopin® clonazepam Antiepileptic, sedative-hypnotic, mood stabilizerl antimanie Larnictal® lamotrigine Antiepileptic Largactil® chlorpromazine Neuroleptic Leponex® clozapine Neuroleptic Levatol® penbutolol ß-Blocker Librium® chlordiazepoxide Sedative-hypnotic Lithane® lithium carbonate Mood
Load more

Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Nootropics: Boost Body and Brain? Report #2445
    NOOTROPICS: BOOST BODY AND BRAIN? REPORT #2445 BACKGROUND: Nootropics were first discovered in 1960s, and were used to help people with motion sickness and then later were tested for memory enhancement. In 1971, the nootropic drug piracetam was studied to help improve memory. Romanian doctor Corneliu Giurgea was the one to coin the term for this drug: nootropics. His idea after testing piracetam was to use a Greek combination of “nous” meaning mind and “trepein” meaning to bend. Therefore the meaning is literally to bend the mind. Since then, studies on this drug have been done all around the world. One test in particular studied neuroprotective benefits with Alzheimer’s patients. More tests were done with analogues of piracetam and were equally upbeat. This is a small fraction of nootropic drugs studied over the past decade. Studies were done first on animals and rats and later after results from toxicity reports, on willing humans. (Source: https://www.purenootropics.net/general-nootropics/history-of-nootropics/) A COGNITIVE EDGE: Many decades of tests have convinced some people of how important the drugs can be for people who want an enhancement in life. These neuro-enhancing drugs are being used more and more in the modern world. Nootropics come in many forms and the main one is caffeine. Caffeine reduces physical fatigue by stimulating the body’s metabolism. The molecules can pass through the blood brain barrier to affect the neurotransmitters that play a role in inhibition. These molecule messengers can produce muscle relaxation, stress reduction, and onset of sleep. Caffeine is great for short–term focus and alertness, but piracetam is shown to work for long-term memory.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • NOOTROPIL® Piracetam
    NOOTROPIL® Piracetam QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 800 mg or 1200 mg of piracetam. Each ml of oral solution contains 200 mg of piracetam EXCIPIENTS NOOTROPIL 800 mg and 1200 mg film-coated tablet: Core: Macrogol 6000 - Colloidal anhydrous silica - Magnesium stearate - Sodium croscarmellose Film-coating: Hydroxypropylmethylcellulose - Titanium dioxide (E171) - Macrogol 400 - Macrogol 6000. NOOTROPIL 200 mg/ml oral solution: Glycerol (85%) - Saccharin sodium - Apricot flavour - Caramel flavour - Methyl parahydroxybenzoate - Propyl parahydroxybenzoate - Sodium acetate - Glacial acetic acid - Purified water. PHARMACEUTICAL FORM NOOTROPIL Tablet 800 and 1200 mg: white, oblong, film-coated tablet, with a bisect line, marked N/N on one side and plain on the other side NOOTROPIL Oral Solution 20%: clear colourless solution INDICATIONS 1. Studies carried out in the elderly suffering from loss of memory, vertigo, a lack of concentration or of alertness, changes of mood, a deterioration in behaviour and personal negligence, demonstrate an improvement in symptoms. These symptoms can also provide an early warning of the onset of pathological ageing such as Alzheimer’s Disease, an Alzheimer type of senile dementia, or the dementia produced by multiple cerebral infarcts. 2. NOOTROPIL is advocated in the treatment of sickle-cell vaso-occlusive crises. 3. Studies have shown some improvement in children with learning difficulties associated with the written word, particularly with textual understanding which cannot be explained by intellectual backwardness, inadequate education or by the family environment. The administration of NOOTROPIL does not replace other measures also well adapted to correct these learning difficulties, such as remedial teaching. DOSAGE AND ADMINISTRATION Oral formulations 1 NOOTROPIL should be administered orally, and may be taken with or without food.
    [Show full text]
  • Valerenic Acid Potentiates and Inhibits GABAA Receptors: Molecular Mechanism and Subunit Specificity
    ARTICLE IN PRESS + MODEL Neuropharmacology xx (2007) 1e10 www.elsevier.com/locate/neuropharm Valerenic acid potentiates and inhibits GABAA receptors: Molecular mechanism and subunit specificity S. Khom a, I. Baburin a, E. Timin a, A. Hohaus a, G. Trauner b, B. Kopp b, S. Hering a,* a Department of Pharmacology and Toxicology, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria b Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria Received 8 December 2006; received in revised form 11 April 2007; accepted 30 April 2007 Abstract Valerian is a commonly used herbal medicinal product for the treatment of anxiety and insomnia. Here we report the stimulation of chloride currents through GABAA receptors (IGABA) by valerenic acid (VA), a constituent of Valerian. To analyse the molecular basis of VA action, we expressed GABAA receptors with 13 different subunit compositions in Xenopus oocytes and measured IGABA using the two-microelectrode voltage-clamp technique. We report a subtype-dependent stimulation of IGABA by VA. Only channels incorporating b2 or b3 subunits were stimulated by VA. Replacing b2/3 by b1 drastically reduced the sensitivity of the resulting GABAA channels. The stimulatory effect of VA on a1b2 receptors was substantially reduced by the point mutation b2N265S (known to inhibit loreclezole action). Mutating the corresponding residue of b1 (b1S290N) induced VA sensitivity in a1b1S290N comparable to a1b2 receptors. Modulation of IGABA was not significantly dependent on incorporation of a1, a2, a3 or a5 subunits. VA displayed a significantly lower efficiency on channels incorporating a4 subunits. IGABA modulation by VA was not g subunit dependent and not inhibited by flumazenil (1 mM).
    [Show full text]
  • Nootropic Concepts
    Nootropic concepts intelligent ingredient for gut health Nootropics definition Nootropic is a substance that enhances cognition and memory and facilitates learning. Nootropics work in many ways to produce a range of benefits across memory, focus, attention, motivation, relaxation, mood, alertness, stress resistance. Bluenesse® Bluenesse® – an innovative, exclusive lemon balm extract, Melissa officinalis (L.) – supports your mental health. It has an immediate effect on focus, concentration, and memory. Furthermore, it supports a calm and good mood and helps to balance the stress hormone cortisol. Bluenesse® - Nootropics concepts Nootropic benefits of Bluenesse® and the underlying mode of action: Bluenesse® - Nootropics concepts – detailed information: Several, double blind, randomized, placebo-controlled, crossover human study results have shown that Bluenesse® supports nootropic effects on demand. Below, the investigated parameter and mode of action is explained per each nootropic application. Vital Solutions GmbH, Hausingerstrasse 6, D-40764 Langenfeld, +49 (0) 2173 109 82 02 [email protected] www.vitalsolutions.biz . Nootropic concepts Cognitive performance support and enhancing learning & memory: Bluenesse® significantly improves cognitive performance, particularly alertness, working memory and mathematic processing by improving the efficiency of neuronal communication. It activates Muscarinic receptors, which are responsible for the efficient flow of information between neurological cells, so-called “oscillation”, leading to
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Treatment Protocol Copyright © 2018 Kostoff Et Al
    Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Diagnostic and Prognostic Advances in Pediatric Mild Traumatic Brain Injury
    Diagnostic and Prognostic Advances in Pediatric Mild Traumatic Brain Injury Lynn Babcock, MD, MS Division of Pediatric Emergency Medicine CME Disclosure Statement Lynn Babcock, MD, MS • I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. • I do not intend to discuss an unapproved or investigative use of a commercial product/device in my presentation. Learning Objectives 1. Implement current diagnostic and prognostic methods for children with mild TBI. 2. Understand how serum biomarkers aid in the diagnosis and prognosis of children with mild TBI. 3. Appreciate advanced neuroimaging as a diagnostic and prognostic tool for children with mild TBI. Case 9 year old boy is playing hockey. Helmeted. Is chasing after the puck, gets tripped (of course accidently) and then gets pile driven into the boards by a much larger 10 year old. He appears unresponsive for a about 1 minute, then he starts to cry. He is unable to get up, and then is helped off the ice. He is dazed and confused for about 5 minutes. His parents bring him into ED. Parents ask: Does he have a brain injury? When can he go back into the game? Primary Injury • “Focal” injuries • “Diffuse” injuries – Direct mechanical damage – Rotational forces critical – Impact – Acceleration, deceleration – Acceleration, deceleration – Results: – Results: • Axonal stretch à axotomy • Coup/counter coup • Primary axotomy • Hemorrhage/infarction • Microhemorrhages • Rapid oncotic injury
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Aniracetam Reduces Glutamate Receptor Desensitization and Slows
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 10936-10940, December 1991 Neurobiology Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus (non-N-methyl-D-aspartate receptor/synapse) JEFFRY S. ISAACSON*t AND ROGER A. NICOLLtt *Physiology Graduate Program and the Departments of SPharmacology and tPhysiology, University of California, San Francisco, CA 94143-0450 Communicated by Floyd E. Bloom, September 16, 1991 ABSTRACT Aniracetam is a nootropic drug that has been and DL-2-amino-5-phosphonovaleric acid (50 ,uM) were shown to selectively enhance quisqualate receptor-mediated added to the medium to block y-aminobutyric acid type A responses inXenopus oocytes injected with brain mRNA and in (GABAA) receptors and NMDA receptors, respectively. In hippocampal pyramidal cells [Ito, I., Tanabe, S., Kohda, A. & the majority of experiments examining iontophoretic re- Sugiyama, H. (1990) J. Physiol. (London) 424, 533-544]. We sponses, tetrodotoxin (0.5-1 1uM) was included to block have used patch clamp recording techniques in hippocampal sodium-dependent action potentials. Currents were recorded slices to elucidate the mechanism for this selective action. We with an Axopatch 1B amplifier from neurons in the CA1 and find that aniracetam enhances glutamate-evoked currents in CA3 pyramidal cell layers and granule cell layer of the whole-cell recordings and, in outside-out patches, strongly dentate gyrus using the "blind" whole-cell recording tech- reduces glutamate receptor desensitization. In addition, nique (15, 16). Patch electrodes (tip diameter = 2 Ium) aniracetam selectively prolongs the time course and increases contained (in mM) either a CsF (110 CsF, 10 CsCl, 10 Hepes, the peak amplitude of fast synaptic currents.
    [Show full text]